Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583) - PubMed (original) (raw)
Clinical Trial
. 2004 Mar 15;22(6):1025-33.
doi: 10.1200/JCO.2004.06.037.
Affiliations
- PMID: 15020604
- DOI: 10.1200/JCO.2004.06.037
Clinical Trial
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)
Eric J Small et al. J Clin Oncol. 2004.
Abstract
Purpose: Antiandrogen withdrawal (AAWD) results in a prostate-specific antigen (PSA) response (decline in PSA level of > or =50%) in 15% to 30% of androgen-independent prostate cancer (AiPCa) patients. Thereafter, adrenal androgen ablation with agents such as ketoconazole (K) is commonly utilized. The therapeutic effect of AAWD alone was compared with simultaneous AAWD and K therapy.
Patients and methods: AiPCa patients were randomized to undergo AAWD alone (n=132), or together with K (400 mg orally [p.o.] tid) and hydrocortisone (30 mg p.o. each morning, 10 mg p.o. each evening; n=128). Patients who developed progressive disease after AAWD alone were eligible for deferred treatment with K.
Results: Eleven percent of patients undergoing AAWD alone had a PSA response, compared to 27% of patients who underwent AAWD and simultaneous K (P=.0002). Objective responses were observed in 2% of patients treated with AAWD alone compared to 20% in patients treated with AAWD/K (P=.02). There was no difference in survival. PSA and objective responses were observed in 32% and 7%, respectively, of patients receiving deferred K, and were more common in patients with prior AAWD response. Treatment with K was well tolerated, and resulted in a decline in adrenal androgen levels, which rose at the time of disease progression.
Conclusion: K has modest activity in AiPCa patients, while AAWD alone has minimal activity. Adrenal androgen levels fall with treatment with K and then climb at the time of progression, suggesting that progressive disease while on K may be due to tachyphylaxis to the adrenolytic properties of K.
Similar articles
- Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Dawson N, Figg WD, Brawley OW, Bergan R, Cooper MR, Senderowicz A, Headlee D, Steinberg SM, Sutherland M, Patronas N, Sausville E, Linehan WM, Reed E, Sartor O. Dawson N, et al. Clin Cancer Res. 1998 Jan;4(1):37-44. Clin Cancer Res. 1998. PMID: 9516950 Clinical Trial. - Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ. Harris KA, et al. J Urol. 2002 Aug;168(2):542-5. J Urol. 2002. PMID: 12131305 - Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y, Kawakami S, Masuda H, Kobayashi T, Hyochi N, Kageyama Y, Kihara K. Fujii Y, et al. BJU Int. 2006 Jun;97(6):1184-9. doi: 10.1111/j.1464-410X.2006.06149.x. BJU Int. 2006. PMID: 16686709 - Endocrine treatment of prostate cancer.
Tammela T. Tammela T. J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31. J Steroid Biochem Mol Biol. 2004. PMID: 15663992 Review. - Maximal androgen blockade for advanced prostate cancer.
Klotz L. Klotz L. Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):331-40. doi: 10.1016/j.beem.2008.01.004. Best Pract Res Clin Endocrinol Metab. 2008. PMID: 18471790 Review.
Cited by
- Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.
Qian SB, Shen HB, Cao QF, Zhang L, Chen YF, Qi J. Qian SB, et al. Int Urol Nephrol. 2015 Mar;47(3):479-84. doi: 10.1007/s11255-015-0919-y. Epub 2015 Feb 10. Int Urol Nephrol. 2015. PMID: 25665794 - Validation and clinical utility of prostate cancer biomarkers.
Scher HI, Morris MJ, Larson S, Heller G. Scher HI, et al. Nat Rev Clin Oncol. 2013 Apr;10(4):225-34. doi: 10.1038/nrclinonc.2013.30. Epub 2013 Mar 5. Nat Rev Clin Oncol. 2013. PMID: 23459624 Free PMC article. Review. - Optimal management of recurrent prostate cancer in older patients.
Kessler ER, Flaig TW. Kessler ER, et al. Drugs Aging. 2012 Nov;29(11):871-83. doi: 10.1007/s40266-012-0021-4. Drugs Aging. 2012. PMID: 23135826 Review. - Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. Ryan CJ, et al. J Clin Oncol. 2010 Mar 20;28(9):1481-8. doi: 10.1200/JCO.2009.24.1281. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159824 Free PMC article. Clinical Trial. - Novel targeted therapeutics for metastatic castration-resistant prostate cancer.
Antonarakis ES, Carducci MA, Eisenberger MA. Antonarakis ES, et al. Cancer Lett. 2010 May 1;291(1):1-13. doi: 10.1016/j.canlet.2009.08.012. Epub 2009 Aug 29. Cancer Lett. 2010. PMID: 19717225 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
- CA03927/CA/NCI NIH HHS/United States
- CA11789/CA/NCI NIH HHS/United States
- CA31946/CA/NCI NIH HHS/United States
- CA31983/CA/NCI NIH HHS/United States
- CA41287/CA/NCI NIH HHS/United States
- CA47577/CA/NCI NIH HHS/United States
- CA60138/CA/NCI NIH HHS/United States
- CA77440/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous